PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MLTX vs. ^GSPC
Performance
Risk-Adjusted Performance
Drawdowns
Volatility

Performance

MLTX vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MoonLake Immunotherapeutics (MLTX) and S&P 500 (^GSPC). The values are adjusted to include any dividend payments, if applicable.

-10.00%0.00%10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
32.97%
12.53%
MLTX
^GSPC

Returns By Period

In the year-to-date period, MLTX achieves a -10.05% return, which is significantly lower than ^GSPC's 25.15% return.


MLTX

YTD

-10.05%

1M

16.59%

6M

32.97%

1Y

19.89%

5Y (annualized)

N/A

10Y (annualized)

N/A

^GSPC

YTD

25.15%

1M

2.97%

6M

12.53%

1Y

31.00%

5Y (annualized)

13.95%

10Y (annualized)

11.21%

Key characteristics


MLTX^GSPC
Sharpe Ratio0.392.53
Sortino Ratio0.913.39
Omega Ratio1.111.47
Calmar Ratio0.503.65
Martin Ratio0.8016.21
Ulcer Index24.95%1.91%
Daily Std Dev50.77%12.23%
Max Drawdown-64.60%-56.78%
Current Drawdown-14.94%-0.53%

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Correlation

-0.50.00.51.00.1

The correlation between MLTX and ^GSPC is 0.13, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Risk-Adjusted Performance

MLTX vs. ^GSPC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for MoonLake Immunotherapeutics (MLTX) and S&P 500 (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MLTX, currently valued at 0.39, compared to the broader market-4.00-2.000.002.004.000.392.53
The chart of Sortino ratio for MLTX, currently valued at 0.91, compared to the broader market-4.00-2.000.002.004.000.913.39
The chart of Omega ratio for MLTX, currently valued at 1.11, compared to the broader market0.501.001.502.001.111.47
The chart of Calmar ratio for MLTX, currently valued at 0.50, compared to the broader market0.002.004.006.000.503.65
The chart of Martin ratio for MLTX, currently valued at 0.80, compared to the broader market0.0010.0020.0030.000.8016.21
MLTX
^GSPC

The current MLTX Sharpe Ratio is 0.39, which is lower than the ^GSPC Sharpe Ratio of 2.53. The chart below compares the historical Sharpe Ratios of MLTX and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Rolling 12-month Sharpe Ratio-1.000.001.002.003.00JuneJulyAugustSeptemberOctoberNovember
0.39
2.53
MLTX
^GSPC

Drawdowns

MLTX vs. ^GSPC - Drawdown Comparison

The maximum MLTX drawdown since its inception was -64.60%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for MLTX and ^GSPC. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-14.94%
-0.53%
MLTX
^GSPC

Volatility

MLTX vs. ^GSPC - Volatility Comparison

MoonLake Immunotherapeutics (MLTX) has a higher volatility of 15.02% compared to S&P 500 (^GSPC) at 3.97%. This indicates that MLTX's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%JuneJulyAugustSeptemberOctoberNovember
15.02%
3.97%
MLTX
^GSPC